上皮性卵巢癌组织中CD44、Nanog的表达及临床意义

Abstract
Figure/Table
References (20)
Related Citation (7)

Download: PDF (506 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the expression levels of CD44 and transcription factor Nanog in tissues with epithelial ovarian cancer and its clinical significance. Methods A total of 80 ovarian tissues of patients with epithelial ovarian cancer treated by operation in Affiliated Hospital of Xuzhou Medical University from January to December 2012 were collected as case group. At the same time, 60 ouarian tissues of patients with benign ovarian tumors were randomly selected as control group. The expression levels of CD44 and Nanog of two groups were detected by immunohistochemistry. Results The positive expression rate of CD44 and Nanog in case group were both higher than the control group, the differences were statistically significant (P < 0.05). The positive rate in patients with tumor diameter ≥ 3 cm, low differentiation, T3+T4 stage of infiltration depth, FIGO stage Ⅲ+Ⅳ, lymph node metastasis were higher than those with tumor diameter <3 cm, medium and high differentiation, T1+T2 stage of infiltration depth, FIGO stage Ⅰ+Ⅱ, no lymph node metastasis, the differences were statistically significant (P < 0.05). Spearman rank correlation analysis showed that a positive correlation between CD44 and Nanog expression in case group was found (rs = 0.592, P < 0.05). The 5-year survival rate in patients with CD44 positive expression was lower than that in patients with CD44 negative expression, and the 5-year survival rate in patients with Nanog positive expression was lower than that in patients with Nanog negative expression, the differences were statistically significant (P < 0.05). Conclusion The up-regulated expression of CD44 and Nanog is involved in the occurrence and development of epithelial ovarian cancer. Early detection of CD44 and Nanog can be used as an important markers for diagnosing epithelial ovarian cancer and evaluating the severity of disease and predicting prognosis.

Key words： Epithelial ovarian cancer CD44 Nanog Clinical significance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Wensheng WEI Min

Cite this article:

DU Wensheng WEI Min. Expression of CD44 and Nanog in tissues with epithelial ovarian cancer and its clinical significance[J]. 中国医药导报, 2018, 15(35): 82-85,93.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I35/82

[1] 于斯雯，韩世愈.卵巢癌干细胞标记物的研究进展[J].现代肿瘤医学，2018，26（10）：1626-1629.
[2] 侯小满，林雪艳，田永杰.CD44和NANOG在上皮性卵巢癌中的表达及其临床意义[J].中国病理生理杂志，2018， 34（3）：549-554.
[3] 黄远见，李巧云，肖娟.转染反义CD44对人鼻咽癌细胞的影响[J].临床合理用药杂志，2018，11（14）：144-145.
[4] Senel F，Kokenek Unal TD，Karaman H，et al. Prognostic value of cancer stem cell markers CD44 and ALDH1/2 in gastric cancer cases [J]. Asian Pac J Cancer Prev，2017， 18（9）：2527-2531.
[5] Hu B，Ma Y，Yang Y，et al. CD44 promotes cell proliferation in non-small cell lung cancer [J]. Oncol Lett，2018， 15（4）：5627-5633.
[6] Md Akhir MKA，Hussin H，Veerakumarasivam A，et al. Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder [J]. Malays J Pathol，2017，39（3）：227-234.
[7] Shrivastava S，Mahantshetty U，Engineer R，et al. Cisplatin chemoradiotherapy vs radiotherapy in FIGO Stage ⅢB squamous cell carcinoma of the uterine cervix：a randomized clinical trial [J]. JAMA Oncol，2018，4（4）：506-513.
[8] Motohara T，Fujimoto K，Tayama S，et al. CD44 variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer [J]. Obstet Gynecol，2016， 127（6）：1003-1011.
[9] Elzarkaa AA，Sabaa BE，Abdelkhalik D，et al. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer：a prospective study [J]. J Cancer Res Clin Oncol，2016，142（5）：949-958.
[10] Sacks JD，Barbolina MV. Expression and Function of CD44 in Epithelial Ovarian Carcinoma [J]. Biomolecules，2015， 5（4）：3051-3066.
[11] 马琳，刘杏巧，张志革，等.CD44及Lgr5在卵巢癌组织中的表达及其与预后的相关性分析[J].标记免疫分析与临床，2017，24（10）：1175-1179，1186.
[12] 李威，姜波健，俞继卫.CD44与CD133蛋白在胃癌组织中的表达及其临床意义[J].中国普外基础与临床杂志，2014，21（1）：21-28.
[13] Wang Z，Wang Q，Wang Q，et al. Prognostic significance of CD24 and CD44 in breast cancer：a meta-analysis [J]. Int J Biol Markers，2017，32（1）：e75-e82.
[14] Sagawa K，Uwa N，Daimon T，et al. Expression of CD44 variant isoforms，CD44v3 and CD44v6，are associated with prognosis in nasopharyngeal carcinoma [J]. J Laryngol Otol，2016，130（9）：843-849.
[15] Wang H，Liu B，Wang J，et al. Reduction of NANOG mediates the inhibitory effect of Aspirin on tumor growth and stemness in colorectal cancer [J]. Cell Physiol Biochem，2017，44（3）：1051-1063.
[16] Liu S，Sun J，Cai B，et al. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer [J]. Tumour Biol，2016，37（7）：9671-9680.
[17] Almozyan S，Colak D，Mansour F，et al. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation [J]. Int J Cancer，2017，141（7）：1402-1412.
[18] You L，Guo X，Huang Y. Correlation of cancer stem-cell markers OCT4，SOX2，and NANOG with clinicopathological features and prognosis in operative patients with rectal cancer [J]. Yonsei Med J，2018，59（1）：35-42.
[19] 李秀娟，赵轶峰，李明霞，等.食管鳞癌组织Nanog表达临床意义分析[J].中华肿瘤防治杂志，2014，21（24）：1962-1965.
[20] Tjhay F，Motohara T，Tayama S，et al. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer [J]. Cancer Sci，2015，106（10）：1421-1428.